Autologous tumor antigens (ATA)

“Autologous tumor antigens” are not a single defined molecule or receptor but rather the heterogeneous set of tumor‑associated and tumor‑specific antigens derived from an individual patient’s own tumor cells. They include neoantigens created by non‑synonymous somatic mutations, as well as overexpressed or aberrantly expressed self proteins that distinguish the patient’s cancer from normal tissues.[4][9] In modern personalized cancer immunotherapy, these antigens are harvested from autologous tumor cells, often enriched for self‑renewing “tumor‑initiating” or cancer stem–like cells in short‑term culture, and then used to load autologous dendritic cells or formulate autologous whole‑cell vaccines.[4][1][7] The loaded dendritic cells or processed tumor cells present peptide epitopes from these antigens on MHC molecules, eliciting predominantly TH1/TH17 and cytotoxic T‑cell responses against the patient’s tumor.[4][1] Clinically, autologous tumor antigen–based products have been tested as personalized vaccines in melanoma, glioblastoma, ovarian, hepatocellular and renal cell cancers, with encouraging signals of delayed but durable tumor regressions, improved progression‑free survival or overall survival in some studies, and generally favorable tolerability.[4][1][7] Because the antigens are highly individualized, they are attractive for overcoming tumor heterogeneity but pose major challenges for identification, manufacturing, and standardization across patients.[2][8][9] These antigens are therefore best viewed as a therapeutic *concept* and a patient‑specific antigen source used by various cell‑based and vaccine platforms, rather than as a discrete drug target comparable to a single receptor, enzyme, or transporter.

Other names

autologous tumor-associated antigensautologous tumor antigen (singular)tumor-associated antigens from autologous tumor cellspatient-specific tumor antigenspersonalized tumor antigensautologous tumor cell antigensautologous tumor antigen-loaded dendritic cell antigens (DC‑ATA antigens)

Act as **antigenic substrates** presented by autologous dendritic cells or other antigen‑presenting cells to activate tumor‑specific cytotoxic T lymphocytes and helper T cells, leading to immune‑mediated killing of tumor cells expressing those antigens[4][1][7]; in autologous cell vaccines, surface‑expressed tumor‑associated antigens from the patient’s own tumor cells are processed and presented by host antigen‑presenting cells, inducing a cytotoxic T‑lymphocyte response and tumor cell death[7][3]